156 related articles for article (PubMed ID: 34345541)
1. Correlation of the Expression of BRAF V600E Mutation With Various Phenotypic Expressions of Thyroid Neoplasms.
Harikrishnan V; Kumari S; Ramkumar S; Sankaran R; Ramalingam S; Sairam T
Cureus; 2021 Jun; 13(6):e16048. PubMed ID: 34345541
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of
Kim H; Kim BH; Kim YK; Kim JM; Oh SY; Kim EH; Lee MJ; Kim JH; Jeon YK; Kim SS; Lee BJ; Kim YK; Kim IJ
J Korean Med Sci; 2018 Jul; 33(27):e75. PubMed ID: 29962924
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
[TBL] [Abstract][Full Text] [Related]
4. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
5. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.
Kurt B; Yalçın S; Alagöz E; Karslıoğlu Y; Yigit N; Günal A; Deveci MS
Endocr Pathol; 2012 Sep; 23(3):135-40. PubMed ID: 22767446
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
7. BRAF(V600E) Mutation, RET/PTC1 and PAX8-PPAR Gamma Rearrangements in Follicular Epithelium Derived Thyroid Lesions - Institutional Experience and Literature Review.
Şahpaz A; Önal B; Yeşilyurt A; Han Ü; Delibaşı T
Balkan Med J; 2015 Apr; 32(2):156-66. PubMed ID: 26167339
[TBL] [Abstract][Full Text] [Related]
8. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
[TBL] [Abstract][Full Text] [Related]
9. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
10. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
Lupi C; Giannini R; Ugolini C; Proietti A; Berti P; Minuto M; Materazzi G; Elisei R; Santoro M; Miccoli P; Basolo F
J Clin Endocrinol Metab; 2007 Nov; 92(11):4085-90. PubMed ID: 17785355
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is rare, benign lesion using modified stringent diagnostic criteria: Reclassification and outcome study.
Cubero Rego D; Lee H; Boguniewicz A; Jennings TA
Ann Diagn Pathol; 2020 Feb; 44():151439. PubMed ID: 31865250
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
[TBL] [Abstract][Full Text] [Related]
13. Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features.
Wahid MHA; Almudhafar RH
J Med Life; 2022 Apr; 15(4):520-525. PubMed ID: 35646190
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
15. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
16. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
17. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.
Basolo F; Torregrossa L; Giannini R; Miccoli M; Lupi C; Sensi E; Berti P; Elisei R; Vitti P; Baggiani A; Miccoli P
J Clin Endocrinol Metab; 2010 Sep; 95(9):4197-205. PubMed ID: 20631031
[TBL] [Abstract][Full Text] [Related]
18. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between BRAF V600E mutation and clinicopathologic features of papillary thyroid carcinoma].
Lu H; Qiu T; Ying J; Guo C; Lyn N
Zhonghua Bing Li Xue Za Zhi; 2014 Dec; 43(12):794-8. PubMed ID: 25623974
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
